Matinas Biopharma Holdings Inc. (MTNB)
NYSE · Healthcare
Matinas Biopharma Holdings Inc. Operating Income 2014–2023
Matinas Biopharma Holdings Inc. annual/quarterly operating income history and growth rate from 2014 to 2023. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Matinas Biopharma Holdings Inc. operating income for the quarter ending March 31, 2023 was -5.6 M, a 12.07% decrease year-over-year.
- Matinas Biopharma Holdings Inc. operating income for the twelve months ending March 31, 2023 was -23.3 M, a 32.15% increase year-over-year.
- Matinas Biopharma Holdings Inc. annual operating income for 2023 was -23.8 M, a 3.35% decrease from 2022.
- Matinas Biopharma Holdings Inc. annual operating income for 2022 was -24.6 M, a 0.59% decrease from 2021.
- Matinas Biopharma Holdings Inc. annual operating income for 2021 was -24.7 M, a 2.18% increase from 2020.
- Matinas Biopharma Holdings Inc. annual operating income for 2020 was -24.2 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Matinas Biopharma Holdings Inc. Operating Income — FAQ
Matinas Biopharma Holdings Inc. (MTNB) operating income over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
What is Matinas Biopharma Holdings Inc.'s operating income?
Matinas Biopharma Holdings Inc. (MTNB) reported operating income of -$24M for fiscal 2023.
Where can I see MTNB's operating income history?
The chart and table above show Matinas Biopharma Holdings Inc.'s operating income by year and by quarter, including the growth rate.